@article{3219445,
    title = "Real-life Experience With Rituximab-CHOP Every 21 or 14 Days in Primary Mediastinal Large B-cell Lymphoma",
    author = "Karakatsanis, S.J. and Bouzani, M. and Symeonidis, A. and Angelopoulou, M.K. and Papageorgiou, S.G. and Michail, M. and Gainaru, G. and Kourti, G. and sachanas, S. and Kalpadakis, C. and Katodritou, E. and Leonidopoulou, T. and Kotsianidis, I. and Hatzimichael, E. and Kotsopoulou, M. and Dimou, M. and Variamis, E. and Boutsis, D. and Kanellias, N. and Dimopoulou, M.N. and Michali, E. and Karianakis, G. and Tsirkinidis, P. and Vadikolia, C. and Poziopoulos, C. and Pigaditou, A. and Vrakidou, E. and Economopoulos, T. and Kyriazopoulou, L. and Siakantaris, M.P. and Kyrtsonis, M.-C. and Anargyrou, K. and Papaioannou, M. and Hatjiharissi, E. and Vervessou, E. and Tsirogianni, M. and Palassopoulou, M. and Stefanoudaki, E. and Zikos, P. and Tsirigotis, P. and Tsourouflis, G. and Assimakopoulou, T. and Verrou, E. and Papadaki, H. and Lampropoulou, P. and Dimopoulos, M.-A. and Pappa, V. and Konstantopoulos, K. and Karmiris, T. and Roussou, P. and Panayiotidis, P. and Pangalis, G.A. and Vassilakopoulos, T.P.",
    journal = "In vivo (Athens, Greece)",
    year = "2022",
    volume = "36",
    number = "3",
    pages = "1302-1315",
    publisher = "International Institute of Anticancer Research",
    doi = "10.21873/invivo.12831",
    keywords = "antineoplastic agent;  cyclophosphamide;  doxorubicin;  prednisone;  rituximab;  vincristine, B cell lymphoma;  human;  prospective study;  retrospective study, Antineoplastic Combined Chemotherapy Protocols;  Cyclophosphamide;  Doxorubicin;  Humans;  Lymphoma, B-Cell;  Prednisone;  Prospective Studies;  Retrospective Studies;  Rituximab;  Vincristine",
    abstract = "Background/Aim: Primary mediastinal large Bcell lymphoma (PMLBCL) is an aggressive B-cell non- Hodgkin lymphoma (NHL), whose prognosis has greatly improved since the incorporation of the anti-CD20 monoclonal antibody rituximab into current therapeutic regimens. Evidence, however, on the optimal time interval between consecutive chemoimmunotherapy (CIT) cycles is still scarce. This study aimed to evaluate the efficacy outcomes of the more commonly administered 3-weekly regimens to the biweekly ones in a PMLBCL patients' population, who were mostly treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone every 21 days (R-CHOP-21) or R-CHOP-14. Patients and Methods: We retrospectively studied our cohort of consecutively treated PMLBCL patients, focusing on their treatment density, in order to determine possible differences in treatment outcomes. Results: CIT, in the form of both RCHOP- 21 as well as R-CHOP-14 (or similar regimens), is highly active in PMLBCL, with low rates of early treatment failure. In our cohort of patients, R-CHOP-14 did not result in a meaningful improvement of freedom from progression (FFP) or overall survival (OS). Conclusion: Both R-CHOP- 14 and R-CHOP-21 are probably equally effective in PMLBCL, yet further, prospective, randomized studies are warranted to clarify whether dose-dense regimens can be associated with better disease control and long-term results. © 2022 International Institute of Anticancer Research. All rights reserved."
}